Page 54 - Read Online

Page 16 of 16 Iruzubieta et al. Metab Target Organ Damage. 2025;5:10 https://dx.doi.org/10.20517/mtod.2024.143

fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. DOI PubMed PMC
60. Puhl RM. Weight stigma and barriers to effective obesity care. Gastroenterol Clin North Am. 2023;52:417-28. DOI PubMed
61. Lazarus JV, Kakalou C, Palayew A, et al. A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and
obesity. Liver Int. 2021;41:2295-307. DOI PubMed
62. Carol M, Pérez-Guasch M, Solà E, et al; LiverHope Consortium Investigators. Stigmatization is common in patients with non-
alcoholic fatty liver disease and correlates with quality of life. PLoS One. 2022;17:e0265153. DOI PubMed PMC
63. Younossi ZM, Alqahtani SA, Alswat K, et al; Global NASH Council. Global survey of stigma among physicians and patients with
nonalcoholic fatty liver disease. J Hepatol. 2024;80:419-30. DOI PubMed
64. Younossi ZM, AlQahtani SA, Funuyet-Salas J, et al; Global NASH Council. The impact of stigma on quality of life and liver disease
burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 2024;6:101066. DOI PubMed PMC
65. Méndez-Sánchez N, Pal SC, Fassio E, Díaz-Ferrer J, Prado-Robles JA. MAFLD: perceived stigma-a single-center Mexican patient
survey. Hepatol Int. 2023;17:507-8. DOI PubMed
66. Shiha G, Korenjak M, Casanovas T, et al. MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol.
2022;77:1717-9. DOI PubMed
67. Ramírez-Mejía MM, Qi X, Abenavoli L, Méndez-Sánchez N. The myth of the stigma of fatty liver: what does the evidence show? Ann
Hepatol. 2024;29:101535. DOI PubMed
68. Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement
on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6:65-72. DOI PubMed
69. Sun M, Rahman AA, Yao VJH. Screening for social determinants of health in underserved populations to promote better outcomes in
ALD and MASLD. Clin Gastroenterol Hepatol. 2025;23:379-80. DOI PubMed
70. Kim RG, Ballantyne A, Conroy MB, Price JC, Inadomi JM. Screening for social determinants of health among populations at risk for
MASLD: a scoping review. Front Public Health. 2024;12:1332870. DOI PubMed PMC
71. Lazarus JV, Mark HE, Anstee QM, et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a
consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60-78. DOI PubMed
72. Lazarus J V, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: are countries ready to
address this silent public health challenge? J Hepatol. 2022;76:771-80. DOI PubMed
73. Alboraie M, Fouad Y, Eslam M. Letter to the editor: MAFLD versus MASLD-which is more appropriate from a global perspective?
Hepatology. 2024;80:E42-3. DOI PubMed
74. Hoofnagle JH, Doo E. Letter to the editor: a multi-society Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology. 2024;79:E91-2. DOI PubMed
75. Fouad Y, Alboraie M, El-Shabrawi M, Zheng MH. Letter to the editor: how F to S turned the premature to be mature? Hepatology.
2024;79:E157-8. DOI PubMed
76. Emanuele E, Minoretti P. Letter to the editor: NAFLD, MAFLD or MASLD? Hepatology. 2024;79:E4. DOI PubMed
77. Alboraie M, Tanwandee T, Xu X, et al. Global multi-societies endorsement of the MAFLD definition. Ann Hepatol. 2024;29:101573.
DOI PubMed
78. Targher G, Tilg H, Byrne CD. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic
approach. Lancet Gastroenterol Hepatol. 2021;6:578-88. DOI PubMed